Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 71.37% | 282.13% | 139.55% | 29.90% | -32.19% |
| Gross Profit | -71.37% | -282.13% | -139.55% | -33.18% | 30.40% |
| SG&A Expenses | 199.78% | 158.45% | 309.47% | 0.91% | 10.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.48% | 229.60% | 193.59% | 20.19% | -20.07% |
| Operating Income | -114.48% | -229.60% | -193.59% | -22.20% | 18.57% |
| Income Before Tax | -99.93% | -194.19% | -190.40% | -25.74% | 14.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.93% | -194.19% | -190.40% | -25.74% | 14.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.93% | -194.19% | -190.40% | -25.74% | 14.16% |
| EBIT | -114.48% | -229.60% | -193.59% | -22.20% | 18.57% |
| EBITDA | -114.28% | -229.79% | -193.88% | -22.23% | 16.53% |
| EPS Basic | 83.26% | 79.16% | 75.11% | 12.77% | 29.80% |
| Normalized Basic EPS | 83.25% | 77.39% | 75.11% | 12.75% | 29.81% |
| EPS Diluted | 83.26% | 79.16% | 75.11% | 12.77% | 29.80% |
| Normalized Diluted EPS | 83.25% | 77.39% | 75.11% | 12.75% | 29.81% |
| Average Basic Shares Outstanding | 1,094.44% | 1,312.10% | 1,066.36% | 44.13% | 22.29% |
| Average Diluted Shares Outstanding | 1,094.44% | 1,312.10% | 1,066.36% | 44.13% | 22.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |